All In Biotech

Drug Trial Radar · NCT04150614

BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron

BMT-08: A Comparative Effectiveness Study of the Efficacy and Safety of Transdermal Granisetron to Ondansetron in the Prevention of Nausea and Vomiting in Patients Undergoing Preparative Chemotherapy and Hematopoietic Stem Cell Transplantation

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

May 14, 2020

Primary completion

Mar 2027

Study completion Mar 2028

Sponsor

Lead sponsor
University of Illinois ChicagoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients undergoing either an autologous or allogeneic hematopoietic stem cell transplant (HSCT) and receiving preparative chemotherapy experience a considerable amount of chemotherapy-induced nausea and vomiting (CINV). Current strategies at reducing CINV in this patient population are suboptimal due to lack of efficacy and supportive evidence, potential for increased adverse events, and drug-drug and drug-disease contraindications.

Conditions

  • Nausea With Vomiting Chemotherapy-Induced

Interventions

  • Granisetron Transdermal PatchDrug

    Antiemetic

  • Intravenous DexamethasoneDrug

    Antiemetic

  • OndansetronDrug

    ondansetron

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare between the two study arms the number of patients achieving complete response (no vomiting and no use of rescue medications) during the acute period (0-24 hours post-chemotherapy) for patients receiving preparative chemotherapy and HSCT.Time frame: 0 hours to 24 hours post-chemotherapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Illinois Cancer Center

    Chicago, Illinois · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.